019170.KS
Shinpoong Pharmaceutical Co., Ltd.
KSC · Healthcare · Drug Manufacturers - Specialty & Generic · KR
KRW 10,100.00
−2.70%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 239.1B | 234.7B | 221.1B | 200.2B | 209.3B |
| Cost of Revenue | 137.8B | 132.3B | 139.3B | 120.0B | 131.3B |
| Gross Profit | 101.3B | 102.4B | 81.8B | 80.3B | 78.0B |
| Operating Expenses | |||||
| R&D Expense | 15.5B | 12.3B | 17.9B | 56.0B | 30.4B |
| SG&A Expense | 50.1B | 28.5B | 33.9B | 36.9B | 35.3B |
| General & Admin Expense | 5.9B | 8.8B | 7.8B | 7.6B | 7.0B |
| Selling & Marketing Expense | 13.9B | 19.8B | 26.1B | 29.3B | 28.4B |
| Other Expenses | 33.1B | 47.3B | 50.5B | 48.5B | (30.4B) |
| Total Operating Expenses | 98.7B | 88.1B | 102.3B | 127.6B | 112.0B |
| Cost and Expenses | 236.5B | 220.4B | 241.5B | 247.6B | 131.3B |
| Operating Income (EBIT) | 2.6B | 14.3B | (20.5B) | (47.4B) | (34.0B) |
| Non-Operating | |||||
| Interest Income | 1.0B | 767.3M | 704.1M | 1.2B | 1.0B |
| Interest Expense | 3.0B | 2.7B | 2.6B | 1.7B | 61.4M |
| Net Interest Income | (2.0B) | (1.9B) | (1.9B) | (545.0M) | 964.6M |
| Other Non-Op Income/Expense | (2.6B) | (5.8B) | 5.8B | (6.0B) | (762.9M) |
| Non-Operating Income (excl Interest) | 2.2B | 3.1B | (8.5B) | 4.3B | 701.4M |
| EBT (Pre-Tax Income) | 5.7M | 8.5B | (14.6B) | (53.4B) | (34.8B) |
| Income Tax Expense | 752.2M | 62.5M | 751.4M | 3.8B | 527.3M |
| Bottom Line | |||||
| Net Income | (815.3M) | 8.8B | (15.4B) | (57.3B) | (35.3B) |
| Earnings from Cont. Ops | (746.5M) | 8.4B | (15.4B) | (57.3B) | (35.3B) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (815.3M) | 8.8B | (15.4B) | (57.3B) | (35.4B) |
| Per Share | |||||
| Basic EPS | (₩10) | ₩172 | (₩300) | (₩1,119) | (₩689) |
| Diluted EPS | (₩10) | ₩172 | (₩300) | (₩1,118) | (₩689) |
| Revenue Per Share | ₩4,452 | ₩4,253 | ₩4,313 | ₩3,908 | ₩4,083 |
| Shares | |||||
| Basic Shares Outstanding | 53.7M | 55.2M | 51.3M | 51.2M | 51.3M |
| Diluted Shares Outstanding | 53.7M | 55.2M | 51.3M | 51.3M | 51.3M |
| Profitability Metrics | |||||
| EBITDA | 14.6B | 25.6B | (27.1M) | (39.8B) | (21.9B) |
| D&A | 11.3B | 11.4B | 12.0B | 11.9B | 12.8B |
| EBIT | 3.3B | 14.3B | (12.0B) | (51.7B) | (34.7B) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026